ANURAS2022-04-012022-06-30ANURAS2022-04-012022-06-30in-bse-fin:OtherExpenses1MemberANURAS2022-04-012022-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss1ANURAS2022-04-012022-06-30ItemsThatWillNotBeReclassifiedToProfitAndLoss2ANURAS2022-04-012022-06-30ItemsThatWillBeReclassifiedToProfitAndLoss1ANURAS2022-04-012022-06-30ItemsThatWillBeReclassifiedToProfitAndLoss2iso4217:INRiso4217:INRxbrli:shares543275ANURASNAINE930P01018ANUPAM RASAYAN INDIA LIMITEDEquity2022-04-012023-03-312022-07-252022-07-19INRMillionsFirst quarterSingle segmentBusiness of custom synthesis and manufacturing of specialty chemicals2022-07-2508:15:002022-07-2509:22:00Not applicable2022-04-012022-06-30UnauditedConsolidated3065577000-94095000297148200018209720000-6940780001266900001215610001570990008733050002405549000565933000056593300010259100088918000191509000037442400000022517000396941000-86840003882570003969410000-868400001002749000103.963.948003.963.948<div> <br></br>
<div>The balance of "Other Income" for the quarter ended June 30, 2022 shows a negative balance primarily on account of foreign exchange loss amounting to Rs. 165.24 million incurred during the quarter.</div> <br></br>
<div><br></br></div> <br></br>
<div>Notes:</div> <br></br>
<div>[1] The above consolidated financial results for the quarter ended June 30, 2022 have been prepared by the Company in accordance with Regulation 33 of SEBI (Listing Obligations & Disclosure Requirements) Regulations 2015 (as amended) and were reviewed and recommended by the Audit Committee of the Board and thereafter were approved and taken on record by the Board of Directors in their meeting held on July 25, 2022. An interim review of the above results has been carried out by the statutory auditors of the Company.</div> <br></br>
<div><br></br></div> <br></br>
<div>[2] The Board of Directors have recommended an interim dividend of INR 0.40 @4% per Equity Share of face value of INR 10/- each.</div> <br></br>
<div><br></br></div> <br></br>
<div>[3] Based on the management approach as defined in Ind AS 108 - Operating Segments, the Chief Operating Decision Maker (CODM) evaluates the company's performance and allocates resources based on an analysis of various performance indicators of business segment/s in which the company operates. The Company is primarily engaged in the business of custom synthesis and manufacturing of specialty chemicals which the management and CODM recognise as the sole business segment. Hence, disclosure of segment-wise information is not required and accordingly not provided.</div> <br></br>
<div><br></br></div> <br></br>
<div>[4] The Company had vide a Share Purchase agreement dated February 01, 2022 acquired 24.96% equity shares of INR 10/- each of TANFAC industries Limited ("TANFAC"). Pursuant to an open offer made by the Company as required by SEBI (SAST) Regulations, the Company acquired a further 0.83% equity shares of TANFAC on May 21, 2022. As a consequence, the Company has obtained de facto effective control over TANFAC with effect from May 21, 2022. Since the control has happened only towards the middle of the quarter, the Company has on the basis of available information, consolidated the performance of TANFAC for this quarter using the equity method.</div> <br></br>
<div><br></br></div> <br></br>
<div>[5] The figures of the previous period have been re-grouped / rearranged and / or recasted wherever considered necessary. The figures of the last quarter are the balancing figures between audited figures in respect of full financial year and audited year to date figures up to the third quarter of the current / previous financial year.</div> <br></br>
<div><br></br></div> <br></br>
<div><br></br></div> <br></br>
<div><br></br></div> <br></br>
<div><br></br></div> <br></br>
<div><br></br></div></div>Other Expenses873305000Gain/ (loss) on remeasurements of the defined benefits plan5943000Income tax (expenses)/income on remeasurements of the defined benefits plan-173100042120000Effective portion of gain/(loss) on hedging instruments in a cash flow hedge-18195000Income tax (expenses)/income on effective portion of gain/(loss) on hedging instruments in a cash flow hedge5299000-128960000